v3.25.2
Condensed Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 107,746 $ 64,380
Short-term marketable securities 144,821 275,324
Assets held for sale 479  
Restricted cash 567  
Prepaid expenses and other current assets 4,992 5,308
Total current assets 258,605 345,012
Long-term marketable securities   28,388
Operating lease right-of-use assets   23,481
Restricted cash   567
Property and equipment, net   11,295
Other non-current assets   5,311
Total assets 258,605 414,054
Current liabilities:    
Accounts payable 8,668 2,441
Accrued clinical and research and development expenses 277 12,521
Accrued expenses and other current liabilities 739 9,437
Accrued restructuring costs 10,646  
Operating lease liabilities, current 578 628
Total current liabilities 20,908 25,027
Operating lease liabilities, non-current 0 28,798
Total liabilities 20,908 53,825
Stockholders' equity:    
Common stock 46 46
Additional paid-in capital 684,743 672,540
Accumulated other comprehensive income (9) 291
Accumulated deficit (447,083) (312,648)
Total stockholders' equity 237,697 360,229
Total liabilities and stockholders' equity $ 258,605 $ 414,054